IFNA2 and chronic myelogenous leukemia, BCR-ABL1 positive: In NordCML007 [84], a single arm phase II clinical trial, CML-CP patients were first treated with dasatinib for three months, and then pegylated IFN-α2b (peg IFN-α2b:15 μg→25 μg/week) was added for 12 months.